Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tectonic TherapeuticTECX -7.84%14 Current Ratio is 22.29 as of Jun. 2026, which is 76% above its 10-year median of 12.65. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Tectonic Therapeutic ranks better than 93.61% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tectonic Therapeutic's current ratio for the quarter that ended in Jun. 2026 was 22.29.
Tectonic Therapeutic has a current ratio of 22.29. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tectonic Therapeutic's Current Ratio or its related term are showing as below:
TECX'
s Current Ratio Range Over the Past 10 Years
Min: 0.61 Med: 12.65 Max: 29.15
Current: 22.29
During the past 5 years, Tectonic Therapeutic's highest Current Ratio was 29.15. The lowest was 0.61. And the median was 12.65.
TECX's Current Ratio is ranked better than 93.61% of 1409
companies
in the Biotechnology industry
Industry Median: 3.85
vs TECX: 22.29
Tectonic Therapeutic (NAS:TECX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tectonic Therapeutic Current Ratio Related Terms
Tectonic Therapeutic Current Ratio Historical Data
* Premium members only.
The historical data trend for Tectonic Therapeutic's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TECX vs ZVRA, SPRY, RLMD: Current Ratio Comparison
For the Biotechnology subindustry, Tectonic Therapeutic's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tectonic Therapeutic Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tectonic Therapeutic's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tectonic Therapeutic (TECX) has a Current Ratio of 22.29 as of Jun. 2026. This is 76% above median its historical median of 12.65. Over the past decade, Tectonic Therapeutic's Current Ratio has ranged from 0.61 to 29.15. According to the industry distribution chart, Tectonic Therapeutic ranks #90 out of 1409 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Tectonic Therapeutic's Current Ratio too high?
Tectonic Therapeutic's current Current Ratio of 22.29 is 76% above median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 29.15. The Biotechnology industry median Current Ratio is 3.85. Tectonic Therapeutic's value of 22.29 is 479% above this industry median. Based on the distribution chart, Tectonic Therapeutic ranks #90 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's Current Ratio compare to ZVRA and SPRY?
According to the Biotechnology industry distribution chart, Tectonic Therapeutic ranks #90 out of 1409 companies for Current Ratio. This places Tectonic Therapeutic in the top 6% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Tectonic Therapeutic's value of 22.29 is 479% above this benchmark. Historically, Tectonic Therapeutic's own Current Ratio has ranged from 0.61 to 29.15 over the past decade. While the company's 10-year median is 12.65 vs. the industry median of 3.85, Tectonic Therapeutic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tectonic Therapeutic's current Current Ratio of 22.29 is 479% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tectonic Therapeutic's current Current Ratio is 22.29, which is 76% above median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current Current Ratio of 22.29. The current Current Ratio is 22.29, which is 76% above median its 10-year median of 12.65 and 479% above the Biotechnology industry median of 3.85. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current Current Ratio is 22.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score
Get the complete analysis for TECX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECX has been successfully added to your 
